Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
12Jan2026
  • Home
  • About
  • News
  • Subscribe
12Jan2026
Cost Curve NewsCost Curve News
Cost Curve News

The Tax-Relief-and-Medicaid-Cuts Bill Nears the Finish Line, With Four Big Implications for the Pharma Industry

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
6 months ago
Keep Reading
Cost Curve News

The Reconciliation Bill Passes the Senate; Orphan IRA ‘Fix’ Included

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
6 months ago
Keep Reading
Cost Curve News

The Government Might Want Amazon and Walmart Involved in Its Direct-to-Consumer Push, Broadening What ‘Pharm-to-Table’ Means

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

The 2028 IRA ‘Negotiations’ Are Going to Be Brutal for Docs, Oncologists Warn

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

New Op-Eds Detail the Anti-MFN Case, Arguing That the Supply Chain Must Be Fixed First

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

Oz Urges PBMs to Do Away With Rebates … Lest the Government Decide to Intervene

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

Oversight of 340B, as Measured by Audits/Audit Findings, Is Woefully Lagging, New Analysis Finds

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

Why You Should Account for Generics When Thinking About U.S. Prices, and How the IRA Will Raise Prices for Seniors

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
Cost Curve News

The Administration Continues to Make Headlines — But Not Policy — on Pharma Issues

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
7 months ago
Keep Reading
121314

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

January 7, 2026

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

January 6, 2026

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

January 5, 2026

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (3,074)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,265)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (2,013)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,824)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,816)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2026 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe